Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT2 | Q96PD7 | 5/20 | 0.50 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.50 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.50 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.45 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14287237 | 0.90 | UCHL1 (0.52) | DGAT2UCHL1MGAT2NR1H2ABHD6 | |
| SCHEMBL14287238 | 0.88 | UCHL1 (0.51) | DGAT2UCHL1MGAT2NR1H2ABHD6 | |
| SCHEMBL14287236 | 0.86 | MGAT2 (0.46) | DGAT2UCHL1MGAT2NR1H2ABHD6 | |
| SCHEMBL14287224 | 0.83 | UCHL1 (0.52) | DGAT2UCHL1MGAT2NR1H2ABHD6 | |
| SCHEMBL30838655 | 0.81 | PTGDR2 (0.44) | NR1H2HDAC1HDAC6 | |
| SCHEMBL14287223 | 0.81 | DGAT2 (0.49) | DGAT2UCHL1MGAT2NR1H2ABHD6 | |
| SCHEMBL17798385 | 0.81 | PTGDR2 (0.44) | NR1H2HDAC1HDAC6 | |
| SCHEMBL14287222 | 0.80 | MGAT2 (0.48) | DGAT2UCHL1MGAT2NR1H2ABHD6 | |
| SCHEMBL16518191 | 0.78 | UCHL1 (0.62) | DGAT2UCHL1MGAT2NR1H2ABHD6 | |
| SCHEMBL19739032 | 0.78 | ESR2 (0.51) | UCHL1NR1H2ABHD6ESR2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080004272-A1 | Compositions and methods for modulating gated ion channels | PAINCEPTOR PHARMA CORPORATION (CA) | 2008-01-03 | — | — | US | disclosed |
| US-20080004272-A1 | Compositions and methods for modulating gated ion channels | PAINCEPTOR PHARMA CORPORATION (CA) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004272-A1 | Compositions and methods for modulating gated ion channels | KCNN3, KCNN2, HCN3 | DGAT2 371/4885UCHL1 3056/4885MGAT2 2914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.